Eric Murphy, Alterome CEO

Al­terome rais­es $132M to take next-gen can­cer drugs aimed at the 'un­drug­gable' in­to clin­ic

With a new $132 mil­lion in hand, Al­terome Ther­a­peu­tics is fi­nal­ly di­vulging what it’s work­ing on.

The on­col­o­gy com­pa­ny will be us­ing its Se­ries B raise to bring two pro­grams — each de­signed to go af­ter spe­cif­ic can­cer-dri­ving mu­ta­tions — to the clin­ic with­in the next year. The San Diego start­up emerged from stealth in 2022, but had not dis­closed its pipeline un­til Wednes­day’s an­nounce­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.